E-LIB Suche - Ergebnisse für: Zeidan, Amer M.

1

Differentiation syndrome associated with treatment with IDH..:

Montesinos, Pau ; Fathi, Amir T. ; de Botton, Stéphane...
Blood Advances. 8 (2024) 10 - p. 2509-2519 , 2024

2

Correction to: Treatment of Myelodysplastic Syndromes for O..:

Kewan, Tariq ; Stahl, Maximillian ; Bewersdorf, Jan Philipp.
Current Hematologic Malignancy Reports. 19 (2024) 3 - p. 151-151 , 2024

Link: https://doi.org/10.1007/..

3

Treatment of Myelodysplastic Syndromes for Older Patients: ..:

Kewan, Tariq ; Stahl, Maximillian ; Bewersdorf, Jan Philipp.
Current Hematologic Malignancy Reports. 19 (2024) 3 - p. 138-150 , 2024

Link: https://doi.org/10.1007/..

4

Comparing venetoclax in combination with hypomethylating ag..:

Badar, Talha ; Nanaa, Ahmad ; Atallah, Ehab...
Blood Cancer Journal. 14 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

5

Sabatolimab plus hypomethylating agents in previously untre..:

Zeidan, Amer M ; Ando, Kiyoshi ; Rauzy, Odile...
The Lancet Haematology. 11 (2024) 1 - p. e38-e50 , 2024

Link: https://doi.org/10.1016/..

6

Hematocrit control and thrombotic risk in patients with pol..:

Chojecki, Aleksander ; Boselli, Danielle ; Dortilus, Allison...
Annals of Hematology. , 2024

Link: https://doi.org/10.1007/..

7

Clinical activity, pharmacokinetics, and pharmacodynamics o..:

Haumschild, Ryan ; Kennerly-Shah, Julie ; Barbarotta, Lisa.
Journal of Oncology Pharmacy Practice. 30 (2024) 4 - p. 721-736 , 2024

Link: https://doi.org/10.1177/..

8

Hypomethylating agents plus venetoclax compared with intens..:

Shimony, Shai ; Bewersdorf, Jan Philipp ; Shallis, Rory M....
Leukemia. 38 (2024) 4 - p. 762-768 , 2024

Link: https://doi.org/10.1038/..

9

Prognostic impact of 'multi-hit' versus 'single hit' TP53 a..:

Badar, Talha ; Nanaa, Ahmad ; Atallah, Ehab...
Haematologica. , 2024

Link: https://doi.org/10.3324/..

10

Clinical Outcomes in Patients With Refractory Anemia With E..:

Zeidan, Amer M. ; Mearns, Elizabeth S. ; Ng, Carmen D....
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) 3 - p. 177-186 , 2024

Link: https://doi.org/10.1016/..

11

Oral decitabine–cedazuridine versus intravenous decitabine ..:

Garcia-Manero, Guillermo ; McCloskey, James ; Griffiths, Elizabeth A...
The Lancet Haematology. 11 (2024) 1 - p. e15-e26 , 2024

Link: https://doi.org/10.1016/..

12

Combination therapy with hypomethylating agents and venetoc..:

Bewersdorf, Jan Philipp ; Shimony, Shai ; Shallis, Rory M....
American Journal of Hematology. , 2024

Link: https://doi.org/10.1002/..

13

Toward a more patient‐centered drug development process in ..:

Efficace, Fabio ; Buckstein, Rena ; Abel, Gregory A....
HemaSphere. 8 (2024) 5 - p. , 2024

Link: https://doi.org/10.1002/..

14

PD-1H/VISTA mediates immune evasion in acute myeloid leukem..:

Kim, Tae Kon ; Han, Xue ; Hu, Qianni...
Journal of Clinical Investigation. 134 (2024) 3 - p. , 2024

Link: https://doi.org/10.1172/..

15

Imetelstat in patients with lower-risk myelodysplastic synd..:

Platzbecker, Uwe ; Santini, Valeria ; Fenaux, Pierre...
The Lancet. 403 (2024) 10423 - p. 249-260 , 2024

Link: https://doi.org/10.1016/..